The reading habits of SmartBrief’s health care and life sciences audiences provide a unique window into the priorities and interests of professionals across these industries, and our newsletter engagement data also sheds light on what’s keeping our readers up at night. We serve health care insurers, clinicians and IT professionals, as well as audiences in pharma and medtech. Here’s what was top of mind for all of them in Q1, as well as a look at what’s next.
The march toward herd immunity
At the start of Q1, just over 4 million COVID-vaccine doses had been administered, supply was tight and questions swirled about the establishment of priority groups, who should be authorized to administer vaccines, and how to reach the vaccine-hesitant, homebound and other populations. SmartBrief readers clicked on these stories and more, getting updates on progress, challenges, and what life would look like after they and their patients were protected.
Fast forward to the end of the quarter. As of March 29, 145.8 million doses of vaccine had been administered, more than 52.6 million Americans were fully vaccinated, and President Joe Biden said 90% of American adults would be eligible for inoculation by April 19. The outlook is brighter, but the emergence of new viral variants and questions about the early rollback of public health restrictions in some areas have complicated the picture.
What’s next: April and May will be telling. AstraZeneca’s vaccine will be vetted by the FDA, and…